Cost Of Revenue - Imexpharm Corp (VN:IMP) - Alpha Spread
I

Imexpharm Corp
VN:IMP

Watchlist Manager
Imexpharm Corp
VN:IMP
Watchlist
Price: 48 650 VND -0.71%
Market Cap: 3.7T VND
Have any thoughts about
Imexpharm Corp?
Write Note

Imexpharm Corp
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Imexpharm Corp
Cost of Revenue Peer Comparison

Comparables:
H
DHT
C
DCL
D
DMC
D
DHG
T
TRA

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
I
Imexpharm Corp
VN:IMP
Cost of Revenue
-â‚«1.3T
CAGR 3-Years
-17%
CAGR 5-Years
-12%
CAGR 10-Years
-12%
H
HaTay Pharmaceutical JSC
VN:DHT
Cost of Revenue
-â‚«1.8T
CAGR 3-Years
5%
CAGR 5-Years
2%
CAGR 10-Years
-10%
C
Cuu Long Pharmaceutical JSC
VN:DCL
Cost of Revenue
-â‚«934B
CAGR 3-Years
-25%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
D
Domesco Medical Import Export Joint Stock Corp
VN:DMC
Cost of Revenue
-â‚«1.4T
CAGR 3-Years
-10%
CAGR 5-Years
5%
CAGR 10-Years
-2%
D
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
Cost of Revenue
-â‚«2.8T
CAGR 3-Years
-9%
CAGR 5-Years
5%
CAGR 10-Years
-4%
T
Traphaco JSC
VN:TRA
Cost of Revenue
-â‚«1.1T
CAGR 3-Years
14%
CAGR 5-Years
5%
CAGR 10-Years
-2%

See Also

What is Imexpharm Corp's Cost of Revenue?
Cost of Revenue
-1.3T VND

Based on the financial report for Jun 30, 2024, Imexpharm Corp's Cost of Revenue amounts to -1.3T VND.

What is Imexpharm Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-12%

Over the last year, the Cost of Revenue growth was -25%. The average annual Cost of Revenue growth rates for Imexpharm Corp have been -17% over the past three years , -12% over the past five years , and -12% over the past ten years .

Back to Top